Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T Cell Counts but Have Minimal Effects on Viral Load by Vaidya, Naveen K. et al.
 
Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T
Cell Counts but Have Minimal Effects on Viral Load
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Vaidya, Naveen K., Libin Rong, Vincent C. Marconi, Daniel R.
Kuritzkes, Steven G. Deeks, and Alan S. Perelson. 2010.
Treatment-mediated alterations in HIV fitness preserve CD4+ T
cell counts but have minimal effects on viral load. PLoS
Computational Biology 6, no. 11: e1001012.
Published Version doi://10.1371/journal.pcbi.1001012
Accessed February 19, 2015 7:42:39 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5355299
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAATreatment-Mediated Alterations in HIV Fitness Preserve
CD4
+ T Cell Counts but Have Minimal Effects on Viral
Load
Naveen K. Vaidya
1, Libin Rong
2, Vincent C. Marconi
3, Daniel R. Kuritzkes
4, Steven G. Deeks
5,6, Alan S.
Perelson
1*
1Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, 2Department of Mathematics and
Statistics, Oakland University, Rochester, Michigan, United States of America, 3Emory University School of Medicine, Division of Infectious Diseases, Atlanta, Georgia,
United States of America, 4Section of Retroviral Therapeutics, Brigham and Women’s Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts,
United States of America, 5Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America, 6San Francisco General
Hospital, San Francisco, California, United States of America
Abstract
For most HIV-infected patients, antiretroviral therapy controls viral replication. However, in some patients drug resistance
can cause therapy to fail. Nonetheless, continued therapy with a failing regimen can preserve or even lead to increases in
CD4
+ T cell counts. To understand the biological basis of these observations, we used mathematical models to explain
observations made in patients with drug-resistant HIV treated with enfuvirtide (ENF/T-20), an HIV-1 fusion inhibitor. Due to
resistance emergence, ENF was removed from the drug regimen, drug-sensitive virus regrown, and ENF was re-
administered. We used our model to study the dynamics of plasma-viral RNA and CD4
+ T cell levels, and the competition
between drug-sensitive and resistant viruses during therapy interruption and re-administration. Focusing on resistant
viruses carrying the V38A mutation in gp41, we found ENF-resistant virus to be 1763% less fit than ENF-sensitive virus in
the absence of the drug, and that the loss of resistant virus during therapy interruption was primarily due to this fitness cost.
Using viral dynamic parameters estimated from these patients, we show that although re-administration of ENF cannot
suppress viral load, it can, in the presence of resistant virus, increase CD4
+ T cell counts, which should yield clinical benefits.
This study provides a framework to investigate HIV and T cell dynamics in patients who develop drug resistance to other
antiretroviral agents and may help to develop more effective strategies for treatment.
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Introduction
Antiretroviral therapy has been used to successfully treat HIV-1
infection. However, a subset of patients develops drug resistance
followed by an observable increase in plasma HIV viral load. This
‘‘virological failure’’ usually triggers a change in the drug regimen.
Here we examine a situation in which patients had developed
resistance to most common drugs and a novel agent, enfuvirtide,
was added to their failing drug regimen. When resistance to
enfuvirtide developed the use of this agent was discontinued in the
hope that drug-sensitive virus would outcompete the resistant virus
and enfuvirtide could be given again. Despite the fact that
resistance developed when enfuvirtide was re-administered and
viral loads were unable to be suppressed, CD4
+ T cell counts were
preserved or increased. Observing increasing CD4
+ T cell counts
without viral suppression is intriguing and suggests that issues of
viral fitness may play a role. Fitness costs have been associated
with drug resistance not only to enfuvirtide but also to other drug
classes [1–6]. Further, despite virologic failure due to the
emergence of drug resistance, continued treatment that imposes
selective pressure on drug sensitive virus and causes outgrowth of
resistant HIV is often associated with benefits such as higher
sustained CD4
+ T cell counts and reduction in the risk of
morbidity and mortality [2–5]. To uncover the nature of the CD4
+
T cell increase and to determine a general principle that may be
useful in developing treatment strategies in the face of drug
resistance, we performed a detailed viral kinetic analysis of a set of
patients treated with enfuvirtide in which longitudinal measure-
ments of drug sensitive and drug resistant viral levels, as well as
CD4 counts, were available.
Enfuvirtide (ENF), formerly called T-20, is a 36 amino acid
synthetic peptide that binds to the HR-1 region of the HIV-1 gp41
molecule, thereby preventing fusion of the viral membrane with
the target cell membrane [7]. It is the first FDA-approved HIV-1
fusion inhibitor [8]. As ENF is expensive and must be admi-
nistered parenterally, it is often reserved for heavily pretreated
patients with limited therapeutic options [9–13]. ENF acts
extracellularly prior to viral entry. This feature provides a number
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that lower the effective intracellular concentrations of other classes
of antiretroviral drugs and little or no drug-drug interactions with
drugs metabolized by the CYP 450 or N-acetyltransferase route
[14].
As with other antiviral drugs, in patients treated with ENF, the
high replication rate of HIV and the low fidelity of HIV reverse
transcriptase can lead to the development of drug resistance [14].
Resistance to ENF occurs due to amino acid substitutions within
the HR-1 region of gp41 at amino acids 36–45 of HIV-1 gp41
with G36D, G36S, G36V, G36E, V38A, V38M, V38E, Q40H,
N42T, and N43D being the most common ENF resistant
mutations [12,13,15]. These mutations result in significantly
reduced binding of ENF to HR-1 [16]. Since ENF is expensive
and poorly tolerated, many individuals interrupt this drug once
virologic failure is confirmed. In a single arm prospective study of
individuals exhibiting virologic failure on ENF, selective interrup-
tion of ENF was not associated with any appreciable increase in
HIV RNA levels, suggesting that the drug had only limited
residual activity and hence its use during failure may not be
warranted [11,17]. Observational data from other groups,
however, have suggested that there may be a CD4
+ T cell benefit
associated with certain ENF-associated mutations [18]. These data
suggest that despite virological failure the drug may have
continued benefit due to alterations in the virus’s pathogenic
effects.
Interruption of ENF in individuals with ENF-resistance is
associated with a rapid decay in the resistant variant [11,13,17].
The reason resistant virus decays in the absence of drug is not fully
understood. Although the rebound of archived more ‘‘fit’’ wild-
type virus is often cited as the major mechanism whereby HIV
resistance decays in the absence of therapy [13,17], ongoing
evolution within the envelop gene and the eventual selection of the
wild-type virus may also account for the loss of ENF resistance
when this drug is interrupted [9].
Despite marked differences in fitness of drug-sensitive and drug-
resistant viruses and evidence of ongoing viral evolution, plasma
HIV-1 RNA levels remain almost constant during ENF interrup-
tion [13]. This apparent paradox suggests that viral fitness may not
be a major determinant of the steady-state level of viremia. To
more fully understand the role of viral fitness as well as other
parameters determining the dynamics of HIV-1 during ENF
interruption, we use mathematical models to study the competition
between ENF sensitive and ENF resistant viruses after the
interruption of ENF and during subsequent re-administration.
We consider only the V38A mutant because this single substitution
in HIV-1 gp41 is the most frequently observed in drug resistant
virus [19] and data on the population size of mutants with V38A
are available [13]. We estimate the rate of forward and backward
mutations, the replication capacity of both drug-sensitive and
drug-resistant viruses, and the efficacy of ENF against viral fusion
when it is re-administered after interruption. We also examine the
effect of target cell level on the dynamics and steady states of drug
sensitive and resistant viruses during ENF interruption and
subsequent re-administration. Lastly, we discuss virus population
turnover and plasma viral RNA levels during the presence and
absence of the drug.
Methods
Patient Data
We obtained wild-type and V38A mutant viral load and CD4
+
T cell data from Department of Medicine, University of
California-San Francisco, CA, USA, San Francisco General
Hospital, San Francisco, CA, USA and Section of Retroviral
Therapeutics, Brigham and Women’s Hospital and Division of
AIDS, Harvard Medical School, Boston, MA, USA. Viral load
and CD4
+ data were obtained for three HIV-1 infected subjects
(P1, P2, and P3) during ENF interruption who continued to
receive the other drugs in their antiretroviral regimen. Before ENF
interruption, subjects P1, P2 and P3 were treated with ENF for 27,
33 and 39 weeks, respectively, and each of them had the V38A
mutation as the predominant virus population (more than 85%
frequency). Viral load and CD4
+ data were also obtained during
subsequent 4-week re-administration of ENF after interruption for
76, 68 and 38 weeks, respectively. For subject P3, the data were
also collected during a second interruption of ENF. Therefore,
there were two data sets during ENF interruption for subject P3.
Mathematical Model
A schematic diagram of the model is shown in Fig. 1. The
model contains five variables: uninfected target cells, T, cells
infected by ENF-sensitive virus, Is, cells infected by ENF-resistant
virus, Ir, ENF-sensitive virus, Vs, and ENF-resistant virus, Vr. The
model assumes that target cells are produced at a constant rate, l,
and die at rate dT. ENF-sensitive virus infects target cells to
produce infected cells, Is, at rate bsTVs, among which a fraction
msbsTVs, become ENF-resistant during the process of reverse
transcription of viral RNA to DNA due to mutation at rate ms.
Similarly, the infection by ENF-resistant virus produces infected
cells, Ir, at rate brTVr, with a fraction mrbrTVr undergoing
backward mutation to the drug sensitive strain at rate mr. Cells
infected by ENF-sensitive and ENF-resistant virus produce new
virions at rates psIs and prIr, and die at rates dIs and dIr,
respectively. Both viruses are cleared at the same rate c per virion.
Whether the V38A mutation in gp41 affects viral production
remains unclear. For simplicity, we assume ps=pr, and describe the
resistance-associated fitness loss only by a reduced infectivity rate,
i.e., br=(12a) bs, where the fitness cost of the mutant virus, a,
satisfies 0#a#1. ENF is a fusion inhibitor and reduces infection of
target cells by free virus. We assume es and er are the efficacies of
ENF against ENF-sensitive and ENF-resistant virus, respectively,
with 0#es, er#1.
In the patient data we analyze the populations of both drug-
resistant and drug-sensitive virus always remain high (above 2.8
log10 HIV RNA copies/ml). Thus, stochastic effects would not be
significant and we formulate the model as a deterministic model –
Author Summary
The impact of antiretroviral drug-resistance on viral load,
CD4
+ T cells, and clinical outcomes is complex. We used
mathematical models to evaluate the benefits of HIV drug
therapy in the presence of drug-resistant virus. As an
example, we considered resistance to enfuvirtide, the first
FDA-approved fusion inhibitor. If viral load increases on
drug therapy due to drug resistance, therapy with this
drug may be stopped. We found that the drug resistant
virus is less fit than the drug-sensitive virus in the absence
of drug, and this fitness disadvantage causes the loss of
drug-resistant virus during drug interruption. After the
drug-sensitive virus replaces resistant virus, enfuvirtide
therapy was re-administered. Analyzing the resulting viral
kinetics, we demonstrate that despite the inability of the
re-administered drug to suppress viral load because of the
continued presence of drug resistant virus, therapy still
provides benefit to the patient by preserving or increasing
peripheral blood CD4
+ T cell levels.
Benefit of HIV Drugs in the Presence of Resistance
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[20,21]. The model is described by the following differential
equations:
dT
dt
~l{dT{(1{es)bsTVs{(1{er)brTVr, ð1Þ
dIs
dt
~(1{ms)(1{es)bsTVs{dIszmr(1{er)brTVr, ð2Þ
dIr
dt
~(1{mr)(1{er)brTVr{dIrzms(1{es)bsTVs, ð3Þ
dVs
dt
~psIs{cVs, ð4Þ
dVr
dt
~prIr{cVr: ð5Þ
As measured by Ki-67 antigen expression, only a small percentage
of CD4
+ T cells in peripheral blood appear to be activated into
proliferation and hence are preferred targets for HIV-1 infection
[22]. Therefore, we take only a fraction of the total CD4 count, i.e.
the activated cells, as targets for HIV-1 infection and estimate this
fraction. The total CD4
+ T cell count is assumed to be given by
(T+Is+Ir)/a, where a denotes the fraction of CD4
+ T cells that are
activated. In principle, a could be time-varying or in particular
depend on the CD4
+ T cell count [22]. However, the CD4 count
of the patients in this study always remains below 200/ml, and
according to the relationship between CD4 count and activated
cell percentage given in [22], a 10-fold change in CD4 count (from
20 to 200/ml) causes only a minor change in activation percentage
(from 8.6% to 10.4%). Therefore, for our study we felt it reason-
able to assume a is constant.
We note that in the study we analyze [13], ENF is given in
combination with other drugs, the infection rates bs, br and the
virus production rates ps, pr that we estimate include the effects of
the other drugs in the background regimen. However, since the
background regimen was failing to suppress HIV replication, these
effects may be minimal. Moreover, the data have taken only V38A
mutants into account with other mutants being included in the
‘‘wild-type’’. Therefore ENF efficacy against wild-type, es, in our
model also incorporates the possible reduction in efficacy due to
other mutants included in the wild-type. Further, loss of V38A
mutation at rate mr, can lead to any of a variety of viral variants
Figure 1. Schematic diagram of the viral dynamic model.
doi:10.1371/journal.pcbi.1001012.g001
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variants carrying the V38A mutation may also carry other
mutations, such as compensatory mutations or other drug
resistance mutations, which may affect the fitness of the drug-
resistant population as well as its level of drug resistance.
We note that there is loss of some free virus due to the infection
of target cells as virus must enter a cell in order to infect. To
incorporate this effect, one can add the terms 2(12es)bsTVs and
2(12er)brTVr to Eqs. (4) and (5), respectively. For the measured
range of T in the subjects considered here, and the estimates of bs
and br determined below, bsT and brT are ,0.05 d
21 which is
,500 times lower than the viral clearance rate c (23 d
21),
indicating that virion loss due to infection will have negligible
effect on the viral dynamics compared to the term 2cV.W e
confirmed this by fitting the model with the terms 2(12es)bsTVs
and 2(12er)brTVr in Eqs. (4) and (5), respectively, in which we
found almost no change in parameter estimates. Therefore, we
neglected virion loss due to infection and left only the viral
clearance term (2cV) in the V equations.
Parameter Estimation
The dynamics of free virus is typically fast in comparison with
that of infected cells [23–25]. Therefore, we assume a quasi-steady
state, which from Eqs. (4) and (5) provides Vs=(ps/c)Is and Vr=(p r/
c)Ir. This simplifies the model leaving only equations for T, Is and
Ir. Further, we set Is(0)=(c/ps)Vs(0) and Ir(0)=(c/pr)Vr(0) for data
fitting as well as all simulations, where Vs(0) and Vr(0) are
determined by direct measurement at the start of interruption or
the start of ENF re-administration.
As measured by Mohri et al. [26], we take the uninfected CD4
+
T cell death rate d=0.01 day
21. Recent estimates show that the
virion clearance rate constant, c, varies between 9.1 day
21 and 36
day
21, with an average of 23 day
21 [25,27]. Therefore, we take
c=23 day
21.
During ENF interruption, we estimate the parameters l (target
cell recruitment rate), bs (drug sensitive virus infection rate), ms
(forward mutation rate), mr (backward mutation rate), a (fitness cost
of ENF-resistance), ps (production rate of drug sensitive virus), d
(infected cell death rate), T0 (initial uninfected target cell
concentration) and a (fraction of CD4
+ T cells that are activated)
by fitting the model to the ENF-sensitive viral load, the ENF-
resistant viral load and the CD4 count data simultaneously for
each patient. Since fewer data points are available during re-
administration of ENF, we fix some parameters at the values
obtained by estimation during ENF interruption; and only
estimate es (ENF efficacy against the sensitive strain), er (ENF
efficacy against the resistant strain), l, T0 and a. We also fitted the
data during ENF interruption and ENF re-administration allowing
the initial concentrations of drug sensitive and drug resistant
viruses to be free parameters, but the fit could not be improved.
We solved Eqs. (1)–(5) numerically using the Runge-Kutta 4
algorithm in Berkeley Madonna [28]. We also used it to obtain the
best-fit parameters via a nonlinear least squares regression method.
The predicted log10 values of the ENF-sensitive and ENF-resistant
viral loads and the CD4 count for each patient were fit to the
corresponding log-transformed data. Of note, to avoid the
difficulty of assigning different weights to the viral loads and
CD4 counts in the objective function being minimized, and give
equal importance to all the widely varied values in the data set, we
fitted the data in the log-scale rather than linear-scale for both viral
loads and CD4 count. Finally, for each best fit parameter estimate,
we provide a 95% confidence interval (CI) using 200 bootstrap
replicates [29], which we performed in MATLAB.
Results
Viral Dynamic Parameters during ENF Interruption
The estimated viral dynamic parameters during ENF interrup-
tion along with their mean and sample standard deviation, and
their 95% confidence interval are summarized in Table 1 and
Table 2, respectively. Using the estimated parameters, we found
the predictions of the model agree well with the data for each of
the study participants (Fig. 2). All the parameters are approx-
imately the same for two ENF-interruptions in P3, suggesting that
the viral dynamic parameters remain stable over time.
We estimated the rates of forward and backward mutation as
2.2460.32610
25 and 1.7360.30610
25, respectively. Even though
the backward mutation rate is slightly lower than the forward
mutation rate, early after ENF interruption the ENF-resistant virus
population is significantly larger than the ENF-sensitive virus
population, and consequently the amount of backward mutation
during the early post ENF interruption is usually higher than the
amount of forward mutation. Although there is a continued
evolution in gp41 after ENF interruption, our results show that
the rate of on-going evolution including backward mutation
accumulation is not sufficient to explain the rapid waning of
ENF-resistant virus. For example, during the first week (month) post
interruption, the contribution of ongoing evolution and backward
mutation to the loss of cells carrying a drug-resistant proviral
genome is only about 0.2 (0.4) cells per ml, which corresponds to the
loss of 26 (70) drug resistant virions per ml per week (month). Since
the contribution of these de-novo mutations is small, we also fitted
the data using the model without de-novo mutation, i.e., ms=mr=0,
Table 1. Estimated parameters during ENF interruption.
Patient lb s ms mr a ps d T0 a
(cells/ml/day) (10
27) (/ml/day) (10
25)( 1 0
25) (virions/infected cell) (1/day) (log10)
P1 343 10.26 2.49 1.80 0.18 4770 0.28 4.16 0.23
P2 1059 9.09 1.78 1.30 0.20 3296 0.28 4.94 0.07
P3 (1
st)
* 911 4.05 2.30 1.80 0.16 2742 0.27 5.33 0.06
P3 (2
nd)
* 845 4.87 2.40 2.00 0.13 3704 0.31 5.16 0.06
Mean 790 7.07 2.24 1.73 0.17 3628 0.29 4.90 0.11
SD 311 3.07 0.32 0.30 0.03 857 0.02 0.52 0.08
*For patient P3, there are two interruptions of ENF.
doi:10.1371/journal.pcbi.1001012.t001
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a range of 0–6%. As the loss of resistant virus due to backward
mutation is negligible, we find the fitness cost, i.e., the reduction of
the infectivity of the resistant virus compared to the wild-type virus,
plays a more important role in the decay of ENF-resistant virus and
the increase of ENF-sensitive virus. Fitting our model to the data
suggests that ENF-resistant virus is 1763% less fit (i.e.,
a=0.1760.03, Table 1) than ENF-sensitive virus in the absence
of ENF. This fitness loss is consistent with the results in Marconi
et al. [13], although they obtained a higher estimate of the relative
fitness cost (25–65%) using a different fitness estimation method.
Our estimates of the virion production rate, ps=pr=36286857
virions day
21, the infected cell death rate, d=0.2960.02 day
21,a n d
the sensitive virus infection rate, bs=7.163.1610
27 ml
21 day
21
(Table 1), are approximately consistent with the estimates
142762000 virions day
21,0 . 3 7 60.19 day
21 and 11.86
14610
27 ml
21 day
21, respectively, in Stafford et al. [30]. However,
t h ee s t i m a t eo fd ismuch smaller than that in some other studies [31].
We also estimated the uninfected cell recruitment rate l=7906311
cellsml
21day
21. Our estimate of asuggests that 11% of CD4
+Tc e ll s
are activated, consistent with the finding that ,10% of CD4
+ Tc e l l s
in peripheral blood are Ki-67
+ in the patients with CD4 count less
than 200 cells/ml [22].
Effectiveness of ENF Re-Administration after ENF-
Interruption
After ENF interruption, ENF was re-administered to the study
subjects for 4 weeks while keeping the same ‘‘background’’
regimen. During this re-administration of ENF, we estimated the
ENF efficacies against sensitive and resistant viruses, es and er.
Estimated values and their 95% confidence intervals are
summarized in Table 3 and Table 4, respectively. Comparisons
of model predictions with the patient data are shown in Fig. 3.
Our estimates indicate that ENF re-administered following
interruption is 6666% effective in reducing infection by ENF-
sensitive virus, while the effectiveness is reduced to 2966% in
reducing infection by ENF-resistant virus. This indicates that
ENF-resistant variants still remain partially sensitive to ENF even
though they have reduced susceptibility. We note that the efficacy
of ENF against drug sensitive virus obtained here is a minimal
estimate as it might have included the reduction of efficacy due to
inclusion of other mutant virus in the drug sensitive virus data.
Other estimated parameters during ENF re-administration
(Table 3) are more or less the same as those estimated during
ENF interruption (Table 1). The continued activity of ENF against
the drug-resistant virus is supported by the apparent immediate
albeit transient and small increase in plasma HIV RNA levels
observed when ENF was interrupted in a larger cohort of
individuals (see Figure 1 in [11]).
Plasma Viral Load
Despite the difference in replication capacity and changes in the
proportion of ENF-sensitive and ENF-resistant viruses (Fig. 2a),
the total plasma viral load remains approximately the same during
ENF interruption (Fig. 2b). The plasma viral load also remains
unchanged during ENF re-administration (Fig. 3) except for a
nominal transient post-readministration suppression followed by a
rebound. This raises a question: what determines the plasma viral
load?
We first studied the effect of ENF-resistant virus fitness cost on
plasma viral load. In Figs. 4a and 5a, we show the plasma viral
load obtained from our model for different fitness costs during
ENF interruption and ENF re-administration, respectively, with
other parameter values held to their estimated values. When we
varied the fitness cost from 5 to 50% we did not find any
observable change in plasma viral load. This suggests that the
fitness cost has a minor role in determining the total viral load. We
next studied the effect of different initial proportions of the mutant
virus at the time of ENF interruption (Fig. 4b) and ENF re-
administration (Fig. 5b). The initial proportion of ENF-resistant
virus does not seem to have any effect on plasma viral load either.
From the model we can calculate the steady state level of
infected cells, I~IszIr, which given our assumption that
ps=pr=p, is proportional to the total viral load, V~VszVr, i.e.
V~pI=c, where an over-bar denotes a steady state value. As the
resistant virus population decays to a low level during ENF
interruption, the net effect of backward mutation on the steady
state is negligible. Therefore, we neglect backward mutation and
obtain the following expression for the steady state total viral load,
V~VszVr:
V~
pl
cd
{
d
(1{ms)bs
: ð6Þ
Note that V is independent of the fitness cost, a.
Similarly, during ENF re-administration we neglect the forward
mutation rate as the sensitive virus replication is largely inhibited,
and obtain the steady state total viral load in the presence of ENF,
VE,a s
Table 2. The 95% confidence intervals obtained by 200 bootstrap replicates for parameter estimates in Table 1.
Patient lb s ms mr a ps d T0 a
(cells/ml/
day)
(10
27)
(/ml/day) (10
25)( 1 0
25)
(virions/
infected cell) (1/day) (log10)
P1 Lower 322 9.1 2.32 0.92 0.17 4582 0.27 4.14 0.22
Upper 394 12.8 5.49 5.08 0.20 4856 0.33 4.18 0.25
P2 Lower 997 8.12 0.82 0.77 0.15 3014 0.27 4.93 0.06
Upper 1335 14.17 5.32 3.83 0.21 3944 0.40 4.94 0.08
P3 Lower 879 4.01 1.12 1.00 0.16 2217 0.19 5.30 0.06
Upper 982 6.00 5.33 4.81 0.24 2942 0.33 5.33 0.07
P4 Lower 810 3.89 2.10 1.21 0.12 3353 0.29 5.12 0.05
Upper 1108 7.45 5.42 5.48 0.15 3787 0.36 5.16 0.08
doi:10.1371/journal.pcbi.1001012.t002
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PLoS Computational Biology | www.ploscompbiol.org 5 November 2010 | Volume 6 | Issue 11 | e1001012Figure 2. Dynamics during ENF interruption. (a) Wild-type (green) and ENF-resistant (red) HIV-1, (b) the total plasma viral load (blue), and (c)
CD4
+ T cells (blue), predicted by the model using estimated parameters (solid curve) and experimentally observed data (N).
doi:10.1371/journal.pcbi.1001012.g002
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pl
cd
{
d
(1{mr)(1{er)(1{a)bs
: ð7Þ
In this case, the total viral load depends upon the fitness cost, a.
However, using our estimated parameters (Table 3), the second
term on the right hand side is ,20-fold smaller than the first term
and hence the effect is negligible as seen in Fig. 5a. Therefore, the
fitness cost again does not have any effect on setting the total viral
load.
We next studied the effect of target cells on the total viral load.
We considered two approaches: one by changing the initial target
cell level and another by changing the recruitment rate of target
cells. We did not observe any effect of the initial target cell level on
the total viral load during ENF interruption (Fig. 4c) or re-
administration (Fig. 5c).
Marked differences in the level of plasma viral load is seen when
the target cell recruitment rate, l, changes while keeping all other
parameters fixed, during both ENF interruption (Fig. 4d) and re-
administration (Fig. 5d). After early transient changes in viral load
upon ENF interruption, the plasma viral load level remains
relatively constant during the interruption with the level related to
the target cell source rate l. A similar result is found during ENF
re-administration except that it takes longer to initially stabilize the
viral load level during ENF re-administration than during ENF
interruption. While we demonstrated the dependence of the viral
load on l (Figs. 4d and 5d), the level of plasma viremia can also be
seen by simulation to depend on p, c and d. This is also supported
by the analytical expressions (6) and (7) for the steady state level of
total virus, which to a good approximation are equal to, pl/(cd),
during ENF interruption and re-administration.
The Target Cell Level
The changes over time of the CD4 count, and of the proportion
of uninfected cells, cell infected with sensitive virus, and cell infected
with resistant virus are shown in Figs. 6a and 6c, respectively. After
ENF re-administration, the proportion of uninfected cells increases,
reaches a peak and then decays to a steady-state level higher than
the level before ENF re-administration. In a study by Deeks et al.
[11] on a larger cohort of individuals, the subjects received an ENF-
based regimen (the same as the one received by individuals in this
study) for 34 weeks (approximately the same period as in our study)
followed by the interruption of ENF. During a screening period of 4
weeks just before the interruption began, they found a negligible
change in CD4
+ T cell counts (mean change: 0.13 cells/ml/week)
suggesting that steady state was reached by the end of this long-term
treatment. They also observed the steady state T cell level after a
long period of ENF interruption. Below we calculate from our
model the steady state level of uninfected CD4
+ T cells to
understand how the uninfected target cell level differs between
long-term ENF interruption and long-term ENF re-administration.
The steady state level of target cells during ENF interruption,
TE, and ENF re-administration, TE, can be calculated from our
model and are given by
TE~
dc
(1{ms)pbs
, ð8Þ
TE~
dc
(1{mr)(1{er)(1{a)pbs
, ð9Þ
respectively. Before ENF is re-administered, er=0, as no drug is
present. After drug is given, er.0 and Eq. (8) shows that the target
cell level should increase. Furthermore, in addition to the efficacy of
the drug against resistant virus, er, the fitness cost, a, also contributes
to the maintenance of a higher level of uninfected target cells during
ENF re-administration. In fact, even if the drug is completely
ineffective against resistant virus (i.e., er=0), and the viral load is
approximately equal during both ENF interruption and ENF re-
administration as shown above, HIV infected patients with ENF re-
administration will still have a higher uninfected target cell level due
to the fitness loss of resistant virus (i.e., for a.0). Above we showed
thatduringre-administrationthetotalviralload,andhencethe total
number of infected cells also stays approximately constant. Hence
the CD4
+ T cell count, which includes both uninfected and infected
CD4
+T cells,isexpected to increase with theincreaseintargetcells.
This is an important result as it shows that even though the resistant
virus becomes dominant during ENF re-administration (Fig. 3), the
CD4
+ T cell count should increase, which represents an immu-
nologic benefit to patients.
Competition between Two Strains
Before ENF interruption, the ENF-resistant viral load is on
average 100-fold higher than ENF-sensitive viral load. After ENF
interruption the proportion of ENF-resistant virus decreases (Fig. 2)
and after several weeks ENF-sensitive virus becomes dominant.
According to our simulations, the time it takes for ENF-sensitive
virus to take over the viral population mainly depends upon the
fitness cost (Fig. 4e) and the initial proportion of ENF-resistant
virus (Fig. 4f). To look at this more closely, we simplify the
problem by neglecting mutation and by assuming the target cell
Table 3. Estimated parameters during ENF re-administration
after interruption.
Patient e
s e
r l T0 a
(cells/ml/day) (log10 cells/ml)
P1 0.71 0.27 206 4.03 0.15
P2 0.67 0.36 1106 4.72 0.07
P3 0.58 0.25 949 4.66 0.08
Mean 0.66 0.29 754 4.47 0.10
SD 0.06 0.06 481 0.38 0.04
doi:10.1371/journal.pcbi.1001012.t003
Table 4. The 95% confidence intervals obtained by 200
bootstrap replicates for parameter estimates in Table 3.
Patient es er l T0 a
(cells/ml/
day)
(log10
cells/ml)
P1 Lower 0.66 0.14 192 3.96 0.11
Upper 0.83 0.28 207 4.05 0.16
P2 Lower 0.63 0.30 1005 4.69 0.07
Upper 0.72 0.47 1303 4.73 0.08
P3 Lower 0.50 0.10 869 4.62 0.07
Upper 0.75 0.29 1023 4.66 0.09
doi:10.1371/journal.pcbi.1001012.t004
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target cell in the presence of drug (i.e. before the interruption).
This results in a system of two linear differential equations in Is and
Ir. Solving these equations, we obtain the following expression for
r(t)=Vr(t)/Vs(t), the ratio of the two strains:
r(t)~r(0)exp
{adt
(1{a)(1{mr)(1{er)

, ð9Þ
where r(0)<100, i.e. resistant virus is approximately 100-fold more
plentiful than sensitive virus. As time off therapy increases the level
of resistant virus falls and r(t) decreases. When r(t),1, the sensitive
virus is the dominant strain. The time, th, for the proportion of
resistant virus to reach r(th) during ENF interruption is
th~
(1{a)(1{mr)(1{er)
ad
ln
r(0)
r(th)
, ð10Þ
As indicated by the above expression, and as seen in Figs. 4e and
4f, an increase in the fitness cost, a, causes the ENF-sensitive virus
to be dominant sooner, while an increase in initial ENF-resistant
virus proportion, r(0), results in a longer time for the ENF-sensitive
virus to be dominant. Varying the T-cell count at the time of
interruption from 50 to 250 or 500 ml
-1 or increasing the T cell
source rate, l, does not significantly impact the proportion of
ENF-resistant virus (Figs. 4g and 4h).
Figure 3. Dynamics during ENF re-administration after interruption. (a) wild-type (green) and ENF-resistant (red) HIV-1, (b) the total plasma
viral load (blue), and (c) CD4
+ T cells (blue), predicted by the model using estimated parameters (solid curve) and experimentally observed data (N).
doi:10.1371/journal.pcbi.1001012.g003
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PLoS Computational Biology | www.ploscompbiol.org 8 November 2010 | Volume 6 | Issue 11 | e1001012Figure 4. Simulation results during ENF interruption. Plasma HIV-1 RNA level (a–d), and V38A mutant virus proportion (e–h), for different V38A
mutant virus fitness costs (a,e), initial V38A mutant virus proportion (b,f), initial T cell counts (c,g) and T cell source rate (d,h). Parameters used are the
average values of P1, P2, P3 in Table 1.
doi:10.1371/journal.pcbi.1001012.g004
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V38A mutant virus fitness costs (a,f), initial V38A mutant virus proportion (b,g), initial T cell counts (c,h), T cell source rate (d,i) and ENF efficacy against
ENF-resistant virus (e,j). Parameters used are the average values in Table 3.
doi:10.1371/journal.pcbi.1001012.g005
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interruption (red) and with ENF re-administration (green). Parameters used are the average values in Tables 1 and 3. The vertical dashed line indicates
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ENF re-administration (Figs. 5f–j). Following ENF re-administra-
tion ENF-resistant virus reemerges rapidly and attains the
proportion r(tw) in an approximate time tw (obtained as in ENF
interruption case above) given by
tw~
1{ms
d½(1{er)(1{a){(1{es) 
ln
r(tw)
r(0)
, ð11Þ
For the parameters in Tables 1 and 2, the virus population
changes more rapidly during ENF re-administration than during
ENF interruption, and the time for the virus population to become
dominated by resistant virus, i.e. for r.1, mainly depends upon
the combined effect of fitness cost and efficacy of ENF against the
ENF-resistant virus. If ENF is sufficiently effective against ENF-
resistant virus or if the fitness cost is sufficiently high, the turnover
is significantly delayed. In addition to ENF efficacy and the fitness
cost, there appear to be nominal effects of the initial ENF-resistant
virus proportion, and target cell generation rate on the turnover of
the virus population during ENF re-administration (Figs. 5g,i).
Benefits of ENF Re-Administration Following an
Interruption
Despite the resistance to ENF, re-administration of ENF might
provide some benefits if ENF has partial activity against resistant
virus. Using our model to study this, we found re-administration of
ENF results in transient nominal viral suppression for about 2
weeks followed by a rapid rebound in plasma HIV-1 RNA level
and then attainment of a steady state viral load higher than the
initial viral load in about 7 weeks (Fig. 5e). This shows that ENF
re-administration is not effective in suppressing plasma viral load.
However, our model simulations show that re-administration of
ENF helps in maintaining a higher CD4
+ T cell level (Fig. 6a).
After ENF re-administration, the CD4 count increases, reaches a
peak and decays to a steady state level higher than the steady state
level before the re-administration. While the CD4
+ T cell count
decreases by 15% in the absence of ENF, re-administration of
ENF results in an increase of the CD4
+ T cell count by 18% over
the treatment period of 3 months (Fig. 6b), which can be clinically
significant. This gain of about 35% in the CD4 count due to ENF
re-administration predicted by our model is consistent with a
,36.8% increase in CD4 count (from 95 cells/ml to 130 cells/ml)
during ENF-treatment observed in a study of 25 individuals [11].
According to our model, this increase is observed because during
re-administration of ENF, ENF-sensitive virus is replaced by ENF-
resistant virus that has less ability to infect CD4
+ target cells
(Fig 6c). Therefore, there appears to be an immunological benefit,
i.e., achieving a higher CD4
+ T cell count, in patients taking ENF,
even though they might suffer virologic failure due to the
emergence of resistance. The level of CD4
+ T cells increases as
fitness cost or/and the efficacy of ENF against ENF-resistant virus
increases because an increase in fitness cost or/and efficacy further
decreases the infectivity of resistant virus.
Discussion
The impact of antiretroviral drug-resistance on viral load, CD4
+
T cell counts and clinical outcomes is complex. Although the
emergence of resistance to protease inhibitors and reverse
transcriptase inhibitors clearly affects viral fitness (as defined in
vitro and in vivo) [2–5,32], its impact on viral load and CD4
+ T
cell counts is unclear. At comparable plasma viral loads, drug
resistant HIV can be associated with more sustained CD4
+ T cell
gains and reduction of the risk of morbidity and mortality
[2,4,5,32] than wild-type (drug-sensitive) HIV. To understand the
mechanism for this apparent beneficial effect on immunologic and
clinical outcomes independent of viremia, we use ENF resistance
as a ‘‘probe’’ to explore the impact of fitness on viral and
immunologic dynamics in vivo. Although the data linking ENF
resistance to viral load, CD4 and clinical outcomes is limited, the
preliminary data that does exist is consistent with the more
extensive literature pertaining to protease inhibitor resistance.
Specifically, despite the emergence of ENF-resistant mutations,
CD4
+ T cell counts have been observed to increase during therapy
as the ENF resistant virus with less capacity to infect T cell
replaces the ENF-sensitive virus. A large prospective study has
recently been completed in which ENF was given as a ‘‘pulse’’ to
determine if the expansion of ENF resistance positively affects
CD4
+ T cell counts. Preliminary data from 3 individuals has
previously been published [13]. Given the richness of this data-set,
we developed a mathematical model to study the benefits of ENF
re-administration after interruption of therapy due to virological
failure.
Interruption of ENF after the emergence of ENF resistance
results in a rapid decay of the resistant variant [13]. One of the key
questions is what factors play a role in the waning of the ENF-
resistant virus and in determining the time for the ENF-sensitive
virus to become dominant. Similar questions arise for the period of
ENF re-administration in which ENF-resistant virus rapidly
increases and takes over the ENF-sensitive virus. Moreover,
despite the rapid turnover of the virus population, the plasma
HIV-1 RNA level remains unchanged during ENF interruption
raising a question of what determines the plasma viral load. In this
study, we took advantage of mathematical models to address these
issues.
Our model, which describes the dynamics of ENF-sensitive
virus, ENF-resistant virus, target cells, cells infected by ENF-
sensitive virus and cells infected by ENF-resistant virus, includes
the fitness cost of ENF-resistant virus as well as forward and
backward mutations. The model was used to fit data concerning
the level of ENF-sensitive viruses, V38A ENF-resistant viruses and
the CD4
+ T cell count from HIV-1 infected patients, who
underwent ENF interruption and subsequent re-administration
while continuing to receive the other drugs in their regimen [13].
The data fitting during ENF interruption allowed us to estimate
the forward mutation rate, the backward mutation rate and the
fitness cost of the ENF-resistant virus along with the virus
production rate, the infected cell death rate, the infection rate,
the source rate of the target cells and the fraction of T cells that
were target cells. Moreover, the data fitting allowed us to estimate
the ENF efficacy against ENF-sensitive and ENF-resistant viruses
during ENF re-administration.
Our parameter estimates, model analysis and numerical
simulations produced several interesting observations. First, the
magnitude of the backward mutation rate of V38A is approxi-
mately the same as that of the forward mutation rate. This
indicates that ongoing viral evolution might have some contribu-
tions to the loss of ENF-resistance during ENF interruption,
the time of ENF re-administration. (b) Bar diagram showing the percentage change of CD4 count at the end of one year without ENF (red) and at the
end of 3 months with ENF re-administration (green). (c) Change over time of the proportion of uninfected cells, T (blue), cells infected with drug-
sensitive virus, Is (green), and cells infected with drug-resistant virus, Ir (red). The vertical dashed line indicates the time of ENF re-administration.
doi:10.1371/journal.pcbi.1001012.g006
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However, we observe that backward mutation barely contributes
to the loss of drug resistant viruses (26 virions/ml in the first week
and 70 virions/ml in the first month post interruption), and thus is
not sufficient to achieve the rapid waning of ENF-resistant viruses
observed when therapy is interrupted. Outgrowth of the wild-type
virus with a fitness advantage in the absence of drug is a more
plausible explanation.
Second, we found that the fitness cost of ENF-resistant
mutations has a major role in the loss of ENF-resistant virus and
the turnover of the virus population during ENF interruption. We
estimated that the ENF-resistant virus is 1763% less fit than the
ENF-sensitive virus. This reduced fitness of V38A ENF-resistant
virus agrees with the experimental finding of reduced fitness of the
V38A mutant virus compared to wild-type virus in vitro [1]. Our
simulations and analysis showed that the time needed for the
sensitive virus to dominate the resistant virus during ENF
interruption is mainly determined by the combined effect of
fitness cost and the initial ENF-resistant virus proportion. Not
surprisingly, the higher the fitness cost, the shorter the turnover
time; and the higher the initial ENF-resistant virus proportion, the
longer the turnover time (Fig. 4e,f). During ENF re-administration,
the ENF efficacy against ENF-resistant virus also plays an
important role in determining the time for the resistant virus to
outcompete sensitive virus. A higher ENF efficacy against ENF-
resistant virus results in a longer turnover time (Fig. 5j).
Interestingly, there is a negligible effect of the target cell level on
determining the turnover time of the virus population (Figs. 4g,h
and 5h,i).
Third, we found that the fitness cost and the initial proportion of
the ENF-resistant virus do not have any observable role in defining
plasma HIV RNA levels. Neither does ENF efficacy during ENF
re-administration contribute to setting plasma viral levels. The
plasma viral RNA level is determined mainly by the target cell
generation rate, l, the virus production rate, p, the infected cell
death rate, d, and the virus clearance rate, c. A higher value of p or
l and/or a lower value of d or c give rise to a higher plasma HIV
RNA level.
Our next observation is related to the advantage or disadvan-
tage of re-administrating the drug following an interruption. Once
the drug is re-administered, the resistant virus rapidly reemerges
and becomes dominant over the sensitive virus. This indicates a
strong selective pressure of the drug on the virus population. The
turnover rate of the virus population is more rapid during the drug
re-administration than during the drug interruption. This shows
that the advantage of the drug-resistant virus over drug-sensitive
virus during the drug re-administration is greater than the
disadvantage of the drug-resistant virus over the drug-sensitive
virus during the drug interruption. The rapid reemergence of the
resistant virus also indicates the persistence of actively replicating
resistant virus as suggested in [33,34]. Our parameter estimates
indicate that ENF when re-administered is ,29% effective against
ENF-resistant virus and ,66% effective against ENF-sensitive
virus. This supports the antiviral activity against ENF-resistant
viruses observed previously [11]. After re-administration of ENF,
our model predicts a small transient suppression of viral load
followed by a rebound to a higher plasma RNA level, consistent
with the pattern shown by the data. This shows that the re-
administration of ENF cannot suppress plasma virus for the long
term.
One of the most interesting results demonstrated by our model
is that despite sustained high levels of viral load, re-administration
of ENF helps in maintaining a significantly higher level of CD4
+ T
cells (Figs. 5e and 6). During ENF re-administration patients can
achieve more than 35% higher CD4
+ T cell count over the period
of 3 months compared to the same patients during ENF inter-
ruption (Fig. 6b). The CD4 count increase predicted by our model
(,35%) is consistent with the CD4 count gain in a study on a
larger cohort of individuals [11] in which the subjects (with the
same background regimen as in our study) maintained a 36.8%
higher CD4 during ENF treatment than during ENF interruption.
This immunologic benefit of ENF occurs even in the presence of
high-level ENF resistance, in agreement with the findings in some
individuals harboring viruses with ENF-resistance mutations under
long-term ENF therapy [35]. This outcome on administering ENF
can be explained by the presence of resistant viruses with a
reduced infection capacity (Figs. 2 and 6c). The treatment alters
the fitness of the virus by selecting the less fit resistant virus that
helps in maintaining a higher CD4 count even though it is
ineffective in suppressing the viral load. A similar effect has been
seen in patients treated with reverse transcriptase and protease
inhibitors such as proD30N, rtK65R and rtM184V [2–5]. The
benefit of the drug is mediated by changes in both the fitness of the
virus and the efficacy of the drug against resistant virus. The CD4
+
T cell level during the drug re-administration increases as the
efficacy of the drug against resistant virus increases or/and the
fitness cost of resistant virus increases.
There are several limitations of this study. The results are based
on limited data from only three subjects. Moreover, there are
fewer data points available during ENF re-administration, which
might produce more uncertainty in the results derived from ENF
re-administration. To gain more confidence in the results obtained
here, extensive studies with more data are necessary. We have
considered the V38A mutant virus as a representative of all ENF-
resistant viruses. However, there are many other mutant viruses,
which may possess different fitness costs and different mutation
rates. It should be noted that in the experiment only the
proportion of V38A was measured, and so there might be other
mutant virus resistant to ENF that would have been included in
the ENF-sensitive viral load. A detailed quasi-species model, as in
Murray and Perelson [36], may provide a better explanation of the
phenomena and help in estimating a more accurate value of the T-
cell benefit. However, such complex models require more detailed
data sets in which the population levels of other members of the
quasi-species are measured. Currently, such data is unavailable.
In summary, we have used mathematical models to help explain
the viral dynamic properties of drug sensitive and resistant viruses
in the presence and the absence of the drug ENF. Our results show
that even though forward and backward mutations occur during
therapy interruption, the primary factor leading to the loss of
resistant virus during therapy interruption is the fitness cost of the
resistant virus. In the presence of drug, the efficacy of drug against
resistant virus is also one of the main factors determining
dominance of the drug resistant virus in the population. More
importantly, even though the drug is ineffective in suppressing
plasma viral load due to the presence of resistant virus, our results
support the concept that continued therapy may have a residual
immunologic benefit by preserving peripheral blood CD4
+ T cell
levels.
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